

# WHO DRUG INFORMATION

Volume 34 • Number 3 • 2020

**Proposed INN: List 124 - COVID-19 (Special Edition)**

**Recommended INN: List 84**

International Nonproprietary Names for Pharmaceutical Substances



**World Health  
Organization**

# WHO Drug Information

WHO Drug Information provides an overview of topics relating to medicines development, regulation, quality and safety. The journal also publishes and reports on guidance documents and includes lists of International Nonproprietary Names for Pharmaceutical Substances (INN), ATC/DDD classification and monographs for The International Pharmacopoeia. It presents and describes WHO policies and activities while reflecting on technical and pharmaceutical topics of international and regional interest.

WHO Drug Information is published four times a year and can be ordered from:

WHO Press, World Health Organization, 1211 Geneva 27, Switzerland.

e-mail: [bookorders@who.int](mailto:bookorders@who.int) or on line at <http://www.who.int/bookorders>

WHO Drug Information can be viewed at:

<http://www.who.int/druginformation>

---

WHO Drug Information, Vol. 34, No. 3, 2020

ISBN 978-92-4-002280-5 (electronic version)

ISBN 978-92-4-002281-2 (print version)

ISSN 1010-9609

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO Drug Information, Vol. 34, No. 3, 2020. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](#).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# WHO Drug Information

## Contents

### Quality Assurance News

- 453** WHO External Quality Assurance Assessment Scheme Phase 9
- 466** WHO Biowaiver Study Project for COVID-19 Outbreak: Dexamethasone Solubility Results for Biopharmaceutical Classification System

### Consultation Documents

- 472** Dissolution Test for Solid Oral Dosage Forms. Draft proposal for revision in *The International Pharmacopoeia*
- 485** WHO Biowaiver Project – Preparation for cycle IV (2021): Prioritization exercise of active pharmaceutical ingredients on the WHO Model List of Essential Medicines for solubility determination and Biopharmaceutics Classification System-based classification
- 492** Zanamivir (Zanamivirum) – Draft proposal for inclusion in *The International Pharmacopoeia*
- 502** Zanamivir powder for inhalation, pre-metered (Zanamiviri pulvis pro inhalatione) – Draft proposal for inclusion in *The International Pharmacopoeia*
- 509** Powders for inhalation (pulvis ad inhalationem) - Draft proposal for inclusion in *The International Pharmacopoeia*
- 516** Good Manufacturing Practices: Water for Pharmaceutical Use
- 540** Revision of Chapter 2.1: General Identification Tests - Draft proposal for inclusion in *The International Pharmacopoeia*
- 548** Policy: Evaluating and Publicly designating Regulatory Authorities as WHO Listed Authorities
- 559** Good Regulatory Practices for Regulatory Oversight of Medical Products
- 597** 3.6 Test for histamine-like substances (vasodepressor substances) - Draft proposal for inclusion in *The International Pharmacopoeia*
- 600** Albendazole chewable tablets (albendazoli compressi manducabiles) - Draft proposal for inclusion in *The International Pharmacopoeia*
- 606** Good Reliance Practices in regulatory decision-making for medical products: high-level principles and considerations

### International Nonproprietary Names (INN)

- 641** Proposed INN List No. 124 – COVID-19 (Special Edition)
- 687** Recommended INN List No. 84

## Abbreviations and websites

CHMP	Committee for Medicinal Products for Human Use (EMA)
EMA	European Medicines Agency ( <a href="http://www.ema.europa.eu">www.ema.europa.eu</a> )
EU	European Union
FDA	U.S. Food and Drug Administration ( <a href="http://www.fda.gov">www.fda.gov</a> )
Health Canada	Federal department responsible for health product regulation in Canada ( <a href="http://www.hc-sc.gc.ca">www.hc-sc.gc.ca</a> )
HPRA	Health Products Regulatory Authority, Ireland ( <a href="http://www.hpra.ie">www.hpra.ie</a> )
HTA	Health Sciences Authority, Singapore ( <a href="http://www.hsa.gov.sg">www.hsa.gov.sg</a> )
ICDRA	International Conference of Drug Regulatory Authorities
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ( <a href="http://www.ich.org">www.ich.org</a> )
IGDRP	International Generic Drug Regulators Programme ( <a href="https://www.igdrp.com">https://www.igdrp.com</a> )
MHLW	Ministry of Health, Labour and Welfare, Japan
MHRA	Medicines and Healthcare Products Regulatory Agency, United Kingdom ( <a href="http://www.mhra.gov.uk">www.mhra.gov.uk</a> )
Medsafe	New Zealand Medicines and Medical Devices Safety Authority ( <a href="http://www.medsafe.govt.nz">www.medsafe.govt.nz</a> )
Ph. Int	<i>The International Pharmacopoeia</i> ( <a href="http://apps.who.int/phint/">http://apps.who.int/phint/</a> )
PRAC	Pharmacovigilance Risk Assessment Committee (EMA)
PMDA	Pharmaceuticals and Medical Devices Agency, Japan ( <a href="http://www.pmda.go.jp/english/index.htm">www.pmda.go.jp/english/index.htm</a> )
Swissmedic	Swiss Agency for Therapeutic Products ( <a href="http://www.swissmedic.ch">www.swissmedic.ch</a> )
TGA	Therapeutic Goods Administration, Australia ( <a href="http://www.tga.gov.au">www.tga.gov.au</a> )
U.S.	United States of America
WHO	World Health Organization ( <a href="http://www.who.int">www.who.int</a> )
WHO MHP	WHO Access to Medicines and Health Products Division ( <a href="http://www.who.int/medicines/en/">www.who.int/medicines/en/</a> )
WHO RPQ	WHO Regulation and Prequalification Department
WHO PQT	WHO Prequalification Unit ( <a href="https://www.who.int/topics/prequalification/en/">https://www.who.int/topics/prequalification/en/</a> )
WHO HPS	WHO Health Product Policy and Standards Department

**Note:** The online version of this issue (freely available at [www.who.int/medicines/publications/druginformation](http://www.who.int/medicines/publications/druginformation)) has direct clickable hyperlinks to the documents and websites referenced

## WHO External Quality Assurance Assessment Scheme Phase 9

### INTRODUCTION

The participation of Pharmaceutical Quality Control Laboratories (PQCLs) in appropriate proficiency testing schemes is an internationally recognised requirement<sup>1&2</sup> as this enables the PQCL to demonstrate, monitor and improve the quality of the analytical services provided. Proficiency testing covers the overall performance of a laboratory, evaluating the process from the reception and storage of samples, the experimental work in the laboratory, the interpretation and the transcription of the data and the conclusions to the reporting sheets. Failure at any of these stages also reflects on the competence of the respective laboratory.

In support of PQCLs, the World Health Organization (WHO) offers proficiency testing through its External Quality Assurance Assessment Scheme (EQAAS) which offers a platform for PQCLs to measure their performance through a confidential system of blind testing. Since 2000, the EQAAS is organized by WHO with the assistance of the European Directorate for the Quality of Medicines and HealthCare (EDQM).

This proficiency testing scheme also serves to demonstrate the reliability of laboratory analytical results by objective means; thereby fostering the establishment of mutual confidence/recognition within collaborating networks, promoting work sharing based on reliance, especially in countries with limited or no quality control testing capabilities.

The EQAAS is facilitated in accordance with the International Organization for Standardization and International Electrotechnical Commission (ISO/IEC) standards for proficiency testing (i.e. ISO/IEC 17043:2010). This Scheme has entered its tenth phase period in 2020. Laboratories across WHO's six regions have participated in the past comparative external assessment studies and more than 1 100 studies involving 33 different tests were carried out.

---


**Marius Brits<sup>1</sup> & Sabine Kopp<sup>2</sup>**

<sup>1</sup> Research Institute for Industrial Pharmacy\* incorporating CENQAM®, WHO Collaborating Centre for the Quality Assurance of Medicines, North-West University, Potchefstroom, South Africa [Marius.Brits@nwu.ac.za](mailto:Marius.Brits@nwu.ac.za)

<sup>2</sup> Norms and Standards for Pharmaceuticals, Health Products Policy and Standards Department, World Health Organization, Geneva, Switzerland [Kopps@who.int](mailto:Kopps@who.int)

## DESCRIPTION OF EQAAS PHASE 9

During EQAAS Phase 9, laboratories were provided with the opportunity to evaluate their performance with regards to three procedures using mebendazole chewable tablets as a common test sample (as depicted in Figure 1).



**Figure 1:** Schematic presentation of analytical procedure bouquet incorporated into EQAAS Phase 9.

- **Procedure 1:** the aim of this procedure was to assess the performance of the laboratory with regards to the determination of the assay by liquid chromatography. Laboratories were requested to determine (in triplicate) the percentage content of mebendazole in mebendazole chewable tablets using the liquid chromatography method from the monograph on mebendazole chewable tablets of *The International Pharmacopoeia*.
- **Procedure 2:** the aim of this procedure was to assess the performance of the laboratories with regards to the identification by Infrared Absorption Spectrophotometry. Laboratories were requested to confirm the polymorphic form of mebendazole present in mebendazole chewable tablets through infrared absorption spectrophotometry; and
- **Procedure 3:** the aim of this procedure was to assess the performance of laboratories with regard to the performance of a dissolution test. Laboratories were requested to carry out the dissolution test and to determine the percentage of mebendazole released at 60 minutes from mebendazole chewable tablets, according to the monograph of *The International Pharmacopoeia* published by WHO.

STATISTICAL METHODS

For procedures 1 and 3, the following approaches applied: Different approaches may be adopted to assign the content of the analyte in the samples. The methods commonly applied in the WHO EQAAS operated in accordance with the Proficiency Testing Scheme developed by the EDQM are the use of a theoretical value or the addition of a known quantity of the analyte to the sample (“true” value) confirmed in the feasibility study or the use of a consensus value based on the results from the participants. To determine the consensus value, robust statistics are generally applied (e.g. the median value, mean interquartile range, Huber’s robust mean) to avoid the influence of “outliers” on the overall mean.

The target standard deviation is set based on experience, or on the reported or expected precision of techniques, and according to fitness for purpose.

*Assigned value*

The assigned values used in this study are the consensus values obtained when calculating the Huber’s robust mean. Table 1 provides a summary of the consensus values and the values obtained during the feasibility studies.

**Table 1:** Summary of consensus values and feasibility study values for procedures 1 and 3

	Consensus Value	Feasibility Value
Procedure 1: Mebendazole Assay	99.25%	99.2%
Procedure 3: Mebendazole Dissolution	69.0%	72.8%

Target standard deviation

The target values for the standard deviation (TSD) for procedures 1 and 3 are summarized in Table 2.

**Table 2:** The target values for the standard deviation (TSD) for procedures 1 and 3

	Target value for TSD
Procedure 1: Mebendazole Assay	0.8%
Procedure 3: Mebendazole Dissolution	3.5%

The target value for the TSD for the assay values took into account the variability between the mean results, calculated at the EDQM on the basis of the individual values reported by the participants.

The uncertainty of the assigned value was found to be negligible compared with the defined TSD and can be ignored in the interpretation of the performance scores.

Scoring

The z-score gives a bias estimate of the result. Absolute z-scores less than 2 are acceptable. A zone of doubtful performance exists for absolute z-scores between 2 and 3. Those do not necessarily have to be unacceptable since there is some uncertainty how close the consensus value is to the true value. An absolute z-score of 3 or more can be interpreted as an unacceptable performance.

Corrective actions should also be triggered when z-scores are frequently in the doubtful zone. For the purposes of this exercise, the calculation of a z-score has then been made for each

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24312](https://www.yunbaogao.cn/report/index/report?reportId=5_24312)

